ImageneBio Inc
Support and Resistance Levels
Past performance
News About IMA
All events for IMA
All deals for IMA
Financial Ratios
Financial Statements
IMA vs Sector & Peers
About ImageneBio Inc
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California. Website inmagenebio.com
Headquarters San Diego, CA, US